Search | Clinical Trials Finder

Conditions: HIV/AIDS
Interventions: Enhanced Peer Intervention; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Brooklyn, New York

Conditions: HIV Infections
Interventions: VH4011499 low dose Injection, VH4011499 high dose Injection, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: HIV/AIDS, Adherence, Medication, Drug Use
Interventions: Text Messaging, Peer Navigation; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: HIV/AIDS
Interventions: Women SHINE, Control; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: HIV Disease
Interventions: α1 Proteinase Inhibitor, Placebos; Biological · Drug
Lead sponsor: Institute for Human Genetics and Biochemistry; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Observation; Other
Lead sponsor: HIV Vaccine Trials Network; Network
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 7 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205); Biological
Lead sponsor: Walter Reed Army Institute of Research (WRAIR); Federal
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions: raltegravir, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: abacavir/lamivudine, abacavir, lamivudine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 52
States / cities: Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more

Conditions: HIV Infections
Interventions: Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption; Drug · Biological · Other
Lead sponsor: Steven Deeks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: enoxaparin, heparin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: HIV Infections
Interventions: Tipranavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 86
States / cities: Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more

Conditions: HIV Infections
Interventions: VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more

Conditions: Virus Diseases, HIV
Interventions: Switch NRTIs as a Backbone to Raltegravir; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections, Sexually Transmitted Diseases, Stigma, Social
Interventions: Information Resources, Social Support, HIV Testing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 29 Years · Male only
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Hiv, Alcohol Drinking, Fall, Cannabis Use
Interventions: Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: HIV Infections
Interventions: POC NAT & Adherence Intervention; Diagnostic Test
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Chiropractic Care; Procedure
Lead sponsor: Tyson Perez, DC, PhD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: HIV Infections
Interventions: CAB LA, RPV LA, RPV, DTG; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 4
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: HIV, STDs
Interventions: Integrated HIV/STI Testing and PrEP Navigation Model; Behavioral
Lead sponsor: My Brother's Keeper, Inc.; Other
Eligibility: 18 Years to 45 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Ridgeland, Mississippi

Conditions: HIV Infections
Interventions: VRC01, VRC01LS, VRC07-523LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 5 Days
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Fort Lauderdale, Florida + 6 more

Search by objective public record fields.

Minority AIDS Initiative Retention and Re-Engagement Project

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users

Women SHINE: Addressing Syndemics and HIV Among Women Through Tech-Based Peer Engagement

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

CAR-T Cells for HIV Infection

Heparin or Enoxaparin in Patients With Cancer

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)

Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests

The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

Integrated Health Services (IHS): A Structural Intervention to Improve HIV/STI Screening and PrEP Navigation in Primary Care

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants